Sanofi Unveils Ground breaking Dupixent Therapy for Chronic Obstructive Pulmonary Disease
Sanofi has introduced Dupixent (dupilumab), a groundbreaking addition to maintenance therapy for adults suffering from uncontrolled chronic obstructive pulmonary disease (COPD) characterised by elevated blood eosinophils.
This approval is intended for patients who are currently receiving treatment with either an inhaled corticosteroid (ICS), a long-acting beta2-agonist (LABA), or a long-acting muscarinic antagonist (LAMA), or a LABA and LAMA combination when an ICS is not suitable.
Dupixent, a fully human monoclonal antibody, works by blocking the signalling of interleukin-4 (IL4) and interleukin-13 (IL13) pathways without suppressing the immune system.
During phase 3 trials, the Dupixent development programme showed substantial clinical benefits by reducing type 2 inflammation. IL4 and IL13 are recognised as pivotal factors in type 2 inflammation, which is closely associated with several related and often co-existing diseases.
This new treatment option marks a significant advancement in COPD care, representing the first such approach in over ten years and offering hope to approximately 220,000 adults in the EU.
COPD is a progressive and debilitating condition that severely impacts daily activities like climbing stairs or walking to the mailbox, leading to feelings of isolation and marginalisation among patients.
With limited treatment advancements until now, the introduction of innovative therapies like Dupixent heralds a new era in disease management for both patients and caregivers alike.
